This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.
The primary endpoint is 1-year local recurrence rate and disease-free survival. We planned to recruit 170 patients who diagnosed as perivascular hepatocellular carcinoma. The patients will be randomized into SBRT group and RFA group as 1:1 ratio.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
170
SBRT for perivascular HCC
RFA for perivascular HCC
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
RECRUITING1-year local recurrence rate
The rate of participants who have recurrence in treating area in 1 year to all the participants
Time frame: 1 year
Disease-free survival
The duration between radomization and recurrence, progression or death
Time frame: 2 years
Overall survival
The duration between radomization and death
Time frame: 2 years
2-year recurrence rate
The rate of participants who have recurrence in 2 years to all the participants
Time frame: 2 years
Adverse events
The incidence rate of severe adverse events
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.